Bioventus (BVS) Stock Forecast, Price Target & Predictions
BVS Stock Forecast
Bioventus stock forecast is as follows: an average price target of $8.83 (represents a -35.59% downside from BVS’s last price of $13.71) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
BVS Price Target
The average price target for Bioventus (BVS) is $8.83 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $2.50. This represents a potential -35.59% downside from BVS's last price of $13.71.
BVS Analyst Ratings
According to 3 Wall Street analysts, Bioventus's rating consensus is 'Buy'. The analyst rating breakdown for BVS stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Bioventus Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 01, 2024 | Caitlin Cronin | Canaccord Genuity | $12.00 | $11.79 | 1.78% | -12.47% |
| Aug 07, 2024 | Chase Knickerbocker | Craig-Hallum | $12.00 | $8.25 | 45.45% | -12.47% |
| May 07, 2024 | William Plovanic | Canaccord Genuity | $8.00 | $5.12 | 56.25% | -41.65% |
| Mar 13, 2024 | Alex Nowak | Craig-Hallum | $9.00 | $5.29 | 70.13% | -34.35% |
| Nov 30, 2022 | - | Goldman Sachs | $2.50 | $1.91 | 30.89% | -81.77% |
The latest Bioventus stock forecast, released on Oct 01, 2024 by Caitlin Cronin from Canaccord Genuity, set a price target of $12.00, which represents a 1.78% increase from the stock price at the time of the forecast ($11.79), and a -12.47% decrease from BVS last price ($13.71).
Bioventus Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 4 |
| Avg Price Target | - | $12.00 | $10.25 |
| Last Closing Price | $13.71 | $13.71 | $13.71 |
| Upside/Downside | -100.00% | -12.47% | -25.24% |
In the current month, the average price target of Bioventus stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Bioventus's last price of $13.71. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 01, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Sep 27, 2024 | Craig-Hallum | Buy | Buy | Hold |
| Aug 07, 2024 | Craig-Hallum | Buy | Buy | Hold |
| May 07, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Dec 07, 2023 | Canaccord Genuity | - | Buy | Upgrade |
| Nov 30, 2022 | Goldman Sachs | Neutral | Neutral | Hold |
| Nov 22, 2022 | Craig-Hallum | - | Hold | Downgrade |
Bioventus's last stock rating was published by Canaccord Genuity on Oct 01, 2024. The company gave BVS a "Buy" rating, the same as its previous rate.
Bioventus Financial Forecast
Bioventus Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $135.42M | - | $137.07M | $119.06M | $125.83M | $137.07M | $140.33M | $117.29M | $130.41M | $108.89M | $109.82M | $81.78M | $98.59M |
| Avg Forecast | $160.94M | $146.15M | $160.22M | $138.60M | $148.10M | $133.24M | $137.60M | $118.37M | $123.96M | $119.00M | $129.23M | $116.57M | $132.59M | $141.59M | $138.33M | $117.69M | $130.23M | $102.39M | $100.97M | $76.54M | $98.08M |
| High Forecast | $160.94M | $146.15M | $160.22M | $138.60M | $148.10M | $133.24M | $137.60M | $118.37M | $123.96M | $119.00M | $129.23M | $116.57M | $132.59M | $141.59M | $138.33M | $117.69M | $130.23M | $102.39M | $100.97M | $76.54M | $98.08M |
| Low Forecast | $160.94M | $146.15M | $160.22M | $138.60M | $148.10M | $133.24M | $137.60M | $118.37M | $123.96M | $119.00M | $129.23M | $116.57M | $132.59M | $141.59M | $138.33M | $117.69M | $130.23M | $102.39M | $100.97M | $76.54M | $98.08M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | 1.09% | - | 1.06% | 1.02% | 0.95% | 0.97% | 1.01% | 1.00% | 1.00% | 1.06% | 1.09% | 1.07% | 1.01% |
Bioventus's average Quarter revenue forecast for Mar 24 based on 1 analysts is $118.37M, with a low forecast of $118.37M, and a high forecast of $118.37M. BVS's average Quarter revenue forecast represents a -12.59% decrease compared to the company's last Quarter revenue of $135.42M (Dec 23).
Bioventus EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | $52.56M | - | $55.23M | $82.85M | $-4.29M | $35.58M | $11.64M | $-7.28M | $9.56M | $7.92M | $5.07M | $32.05M | $13.18M |
| Avg Forecast | $21.88M | $19.87M | $21.78M | $18.84M | $20.13M | $18.11M | $18.70M | $16.09M | $16.85M | $16.18M | $17.57M | $15.85M | $18.02M | $19.25M | $18.80M | $16.00M | $17.70M | $13.92M | $13.72M | $10.40M | $13.33M |
| High Forecast | $21.88M | $19.87M | $21.78M | $18.84M | $20.13M | $18.11M | $18.70M | $16.09M | $16.85M | $16.18M | $17.57M | $15.85M | $18.02M | $19.25M | $18.80M | $16.00M | $17.70M | $13.92M | $13.72M | $10.40M | $13.33M |
| Low Forecast | $21.88M | $19.87M | $21.78M | $18.84M | $20.13M | $18.11M | $18.70M | $16.09M | $16.85M | $16.18M | $17.57M | $15.85M | $18.02M | $19.25M | $18.80M | $16.00M | $17.70M | $13.92M | $13.72M | $10.40M | $13.33M |
| Surprise % | - | - | - | - | - | - | - | - | 3.12% | - | 3.14% | 5.23% | -0.24% | 1.85% | 0.62% | -0.46% | 0.54% | 0.57% | 0.37% | 3.08% | 0.99% |
1 analysts predict BVS's average Quarter EBITDA for Mar 24 to be $16.09M, with a high of $16.09M and a low of $16.09M. This is -69.39% lower than Bioventus's previous annual EBITDA (Dec 23) of $52.56M.
Bioventus Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | $-6.10M | - | $-3.68M | $-100.02M | $-44.87M | $3.17M | $-8.01M | $-14.81M | $-1.89M | $-1.07M | $-4.13M | $24.94M | $2.78M |
| Avg Forecast | $16.40M | $9.01M | $16.58M | $5.71M | $7.36M | $1.04M | $4.31M | $-4.27M | $1.23M | $-1.28M | $-213.50K | $-9.61M | $3.08M | $7.87M | $9.98M | $3.05M | $11.29M | $9.00M | $8.75M | $145.88M | $14.73M |
| High Forecast | $16.40M | $9.01M | $16.58M | $5.71M | $7.36M | $1.04M | $4.31M | $-4.27M | $1.23M | $-1.28M | $-213.50K | $-9.61M | $3.08M | $7.87M | $9.98M | $3.05M | $11.29M | $9.00M | $8.75M | $175.05M | $14.73M |
| Low Forecast | $16.40M | $9.01M | $16.58M | $5.71M | $7.36M | $1.04M | $4.30M | $-4.27M | $1.23M | $-1.28M | $-213.50K | $-9.61M | $3.08M | $7.87M | $9.98M | $3.05M | $11.29M | $9.00M | $8.75M | $116.70M | $14.73M |
| Surprise % | - | - | - | - | - | - | - | - | -4.97% | - | 17.24% | 10.41% | -14.59% | 0.40% | -0.80% | -4.85% | -0.17% | -0.12% | -0.47% | 0.17% | 0.19% |
Bioventus's average Quarter net income forecast for Dec 22 is $3.08M, with a range of $3.08M to $3.08M. BVS's average Quarter net income forecast represents a -3.10% decrease compared to the company's last Quarter net income of $3.17M (Sep 22).
Bioventus SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | $78.36M | - | $74.84M | $80.86M | $77.67M | $84.33M | $89.62M | $86.12M | $80.88M | $69.64M | $69.05M | $34.69M | $61.97M |
| Avg Forecast | $96.24M | $87.40M | $95.81M | $82.88M | $88.56M | $79.68M | $82.29M | $70.78M | $74.13M | $71.16M | $77.28M | $69.71M | $79.29M | $84.67M | $82.72M | $70.38M | $77.88M | $61.23M | $60.38M | $45.77M | $58.65M |
| High Forecast | $96.24M | $87.40M | $95.81M | $82.88M | $88.56M | $79.68M | $82.29M | $70.78M | $74.13M | $71.16M | $77.28M | $69.71M | $79.29M | $84.67M | $82.72M | $70.38M | $77.88M | $61.23M | $60.38M | $45.77M | $58.65M |
| Low Forecast | $96.24M | $87.40M | $95.81M | $82.88M | $88.56M | $79.68M | $82.29M | $70.78M | $74.13M | $71.16M | $77.28M | $69.71M | $79.29M | $84.67M | $82.72M | $70.38M | $77.88M | $61.23M | $60.38M | $45.77M | $58.65M |
| Surprise % | - | - | - | - | - | - | - | - | 1.06% | - | 0.97% | 1.16% | 0.98% | 1.00% | 1.08% | 1.22% | 1.04% | 1.14% | 1.14% | 0.76% | 1.06% |
Bioventus's average Quarter SG&A projection for Mar 24 is $70.78M, based on 1 Wall Street analysts, with a range of $70.78M to $70.78M. The forecast indicates a -9.66% fall compared to BVS last annual SG&A of $78.36M (Dec 23).
Bioventus EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | $-0.10 | - | $-0.06 | $-1.61 | $-0.72 | $0.05 | $-0.13 | $-0.24 | $-0.03 | $-0.03 | $-0.10 | $0.60 | $0.07 |
| Avg Forecast | $0.26 | $0.14 | $0.26 | $0.09 | $0.11 | $0.02 | $0.07 | $-0.07 | $0.02 | $-0.02 | $-0.00 | $-0.15 | $0.05 | $0.12 | $0.16 | $0.05 | $0.18 | $0.14 | $0.14 | $0.28 | $0.23 |
| High Forecast | $0.26 | $0.14 | $0.26 | $0.09 | $0.11 | $0.02 | $0.07 | $-0.07 | $0.02 | $-0.02 | $-0.00 | $-0.15 | $0.05 | $0.12 | $0.16 | $0.05 | $0.18 | $0.14 | $0.14 | $0.28 | $0.23 |
| Low Forecast | $0.26 | $0.14 | $0.26 | $0.09 | $0.11 | $0.02 | $0.07 | $-0.07 | $0.02 | $-0.02 | $-0.00 | $-0.15 | $0.05 | $0.12 | $0.16 | $0.05 | $0.18 | $0.14 | $0.14 | $0.28 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | -5.05% | - | 17.64% | 10.73% | -14.99% | 0.42% | -0.83% | -5.04% | -0.20% | -0.21% | -0.73% | 2.13% | 0.30% |
According to 1 Wall Street analysts, Bioventus's projected average Quarter EPS for Dec 22 is $0.05, with a low estimate of $0.05 and a high estimate of $0.05. This represents a -6.74% decrease compared to BVS previous annual EPS of $0.05 (Sep 22).
BVS Forecast FAQ
Is Bioventus a good buy?
Yes, according to 3 Wall Street analysts, Bioventus (BVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of BVS's total ratings.
What is BVS's price target?
Bioventus (BVS) average price target is $8.83 with a range of $2.5 to $12, implying a -35.59% from its last price of $13.71. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Bioventus stock go up soon?
According to Wall Street analysts' prediction for BVS stock, the company can go down by -35.59% (from the last price of $13.71 to the average price target of $8.83), down by -12.47% based on the highest stock price target, and down by -81.77% based on the lowest stock price target.
Can Bioventus stock reach $20?
BVS's average twelve months analyst stock price target of $8.83 does not support the claim that Bioventus can reach $20 in the near future.
What are Bioventus's analysts' financial forecasts?
Bioventus's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $537.3M (high $537.3M, low $537.3M), average EBITDA is $73.04M (high $73.04M, low $73.04M), average net income is $8.44M (high $8.45M, low $8.43M), average SG&A $321.31M (high $321.31M, low $321.31M), and average EPS is $0.132 (high $0.132, low $0.132). BVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $605.91M (high $605.91M, low $605.91M), average EBITDA is $82.36M (high $82.36M, low $82.36M), average net income is $47.71M (high $47.71M, low $47.71M), average SG&A $362.34M (high $362.34M, low $362.34M), and average EPS is $0.745 (high $0.745, low $0.745).
Did the BVS's actual financial results beat the analysts' financial forecasts?
Based on Bioventus's last annual report (Dec 2023), the company's revenue was $100K, which missed the average analysts forecast of $488.76M by -99.98%. Apple's EBITDA was $38K, missing the average prediction of $66.44M by -99.94%. The company's net income was $0, missing the average estimation of $-9.877M by -100.00%. Apple's SG&A was $59.4K, missing the average forecast of $292.28M by -99.98%. Lastly, the company's EPS was $0, missing the average prediction of $-0.154 by -100.00%. In terms of the last quarterly report (Dec 2023), Bioventus's revenue was $135.42M, beating the average analysts' forecast of $123.96M by 9.25%. The company's EBITDA was $52.56M, beating the average prediction of $16.85M by 211.91%. Bioventus's net income was $-6.096M, missing the average estimation of $1.23M by -597.05%. The company's SG&A was $78.36M, beating the average forecast of $74.13M by 5.71%. Lastly, the company's EPS was $-0.0966, missing the average prediction of $0.0191 by -604.54%